-
1h 32sPart 3 | Session 1 Session 3.1 & 3.2: Keynote & Controversies
-
59m 54sPart 3 | Session 2 Session 3.3: Live Cases and Discussion
-
51m 53s
-
1h 3m 33sPart 3 | Session 4 Session 3.4: Debates
-
47m
-
1h 1m 7sPart 1 | Session 1 Session 1.1: Next Level Structural Heart Interventions
-
1h 2m 19sPart 1 | Session 2 Session 1.2: Live Cases and Discussion
-
59m 47sPart 1 | Session 4 Session 1.3: Practical Perspectives in the Context of TAVI
-
1h 2m 44sPart 1 | Session 5 Session 1.4: Live Cases and Discussions
-
44m 31sPart 1 | Session 6 BREAKOUT: Current Data and Future Direction in LAAC
-
1h 1m 36sPart 2 | Session 1 Session 2.1: Strategies for Calcified Coronary Lesions Anno 2022
-
57m 43sPart 2 | Session 2 Session 2.2: Live Cases and Discussion
-
45m 25s
-
1h 1m 32sPart 2 | Session 4 Session 2.3: Practical Pearls Towards a More Advanced CTO Programme
-
56m 37sPart 2 | Session 5 Session 2.4: Live Cases and Discussion
-
56m 12s
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Day One: Structural Heart Disease
Part 2
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Faculty Biographies
Ziad A Ali
Dr Ali is a board-certified cardiologist specialising in interventional and structural cardiology at St Francis Hospital and Heart Center in Roslyn, New York.
Ziad is an internationally renowned expert in complex high-risk indicated percutaneous coronary interventions (CHIP) including the treatment of chronic total occlusions (CTO) where the arteries in the heart become completely blocked.
Ziad specialises in the management of cardiovascular disease in patients with pre-existing kidney disease.
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Zsolt Piroth
Dr Zsolt Piroth is an interventional cardiologist, and serves as Deputy Head of the Adult Cardiology Department of the György Gottsegen Hungarian Institute of Cardiology, Hungary. A Fellow of the European Society of Cardiology, he is the Secretary of the Intensive Working Group of the Hungarian Society of Cardiology and was Vice-Chair of the Interventional Working Group of the Hungarian Society of Cardiology.